Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab

被引:48
作者
Genant, Harry K. [1 ,2 ]
Libanati, Cesar [3 ]
Engelke, Klaus [4 ,5 ]
Zanchetta, Jose R. [6 ]
Hoiseth, Arne [7 ]
Yuen, Chui Kin [8 ]
Stonkus, Sigtas [9 ]
Bolognese, Michael A. [10 ]
Franek, Edward [11 ,12 ]
Fuerst, Thomas [13 ]
Radcliffe, Hoi-Shen [14 ]
McClung, Michael R. [15 ]
机构
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Synarc Inc, San Francisco, CA 94105 USA
[3] Amgen Inc, Thousand Oaks, CA 91320 USA
[4] Univ Erlangen Nurnberg, Inst Med Phys, D-91052 Erlangen, Germany
[5] Synarc Inc, Hamburg, Germany
[6] Inst Invest Metab, Buenos Aires, DF, Argentina
[7] Curato Rentgen, Oslo, Norway
[8] SIGMA Canadian Menopause Soc, Vancouver, BC V6H 1E5, Canada
[9] Klaipeda Univ Hosp, LT-92228 Klaipeda, Lithuania
[10] Bethesda Hlth Res, Bethesda, MD 20879 USA
[11] Cent Clin Hosp MSWiA, PL-02507 Warsaw, Poland
[12] Polish Acad Sci, Med Res Ctr, PL-02106 Warsaw, Poland
[13] Synarc Inc, Newark, CA 94560 USA
[14] Amgen Ltd, Cambridge CB4 OWD, England
[15] Oregon Osteoporosis Ctr, Portland, OR 97213 USA
关键词
Bone mineral density; Bone mineral content; Denosumab; Hip; Osteoporosis; Quantitative computed tomography; QUANTITATIVE COMPUTED-TOMOGRAPHY; BONE-MINERAL DENSITY; OSTEOPROTEGERIN LIGAND; NONINVASIVE ASSESSMENT; FRACTURES; TURNOVER; STRENGTH; ALENDRONATE; PHASE-2; AMG-162;
D O I
10.1016/j.bone.2013.07.011
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
In the FREEDOM study, denosumab treatment (60 mg every 6 months) decreased bone resorption, increased bone mineral density (BMD), and reduced new vertebral, nonvertebral, and hip fractures over 36 months in postmenopausal women with osteoporosis. In a subset of these women, hip quantitative computed tomography (QCT) was performed at baseline and months 12, 24, and 36. These scans were analyzed using Medical Image Analysis Framework (MIAF) software, which allowed assessment of total hip integral, trabecular, subcortical, and cortical compartments; the cortical compartment was further divided into 2 areas of interest (outer and inner cortex). This substudy reports changes in BMD and bone mineral content (BMC) from baseline and compared placebo with denosumab over 36 months of treatment (placebo N = 26; denosumab N = 36). Denosumab treatment resulted in significant improvements in total hip integral volumetric BMD (vBMD) and BMC from baseline at each time point. At month 36, the mean percentage increase from baseline in total hip integral vBMD and BMC was 6.4% and 4.8%, respectively (both p < 0.0001). These gains were accounted for by significant increases in vBMD and BMC in the trabecular, subcortical, and cortical compartments. In the placebo group, total hip integral vBMD and BMC decreased at month 36 from baseline by -1.5% and -2.6%, respectively (both p < 0.05). The differences between denosumab and placebo were also significant at months 12, 24, and 36 for integral, trabecular, subcortical, and cortical vBMD and BMC (all p < 0.05 to <0.0001). While the largest percentage differences occurred in trabecular vBMD and BMC, the largest absolute differences occurred in cortical vBMD and BMC. In summary, denosumab significantly improved both vBMD and BMC from baseline and placebo, assessed by QCT MIAF, in the integral, trabecular, subcortical, and cortical hip compartments, all of which are relevant to bone strength. (C) 2013 The Authors. Published by Elsevier Inc All rights reserved.
引用
收藏
页码:482 / 488
页数:7
相关论文
共 36 条
[1]
Bone strength and its determinants [J].
Ammann, P ;
Rizzoli, R .
OSTEOPOROSIS INTERNATIONAL, 2003, 14 (Suppl 3) :S13-S18
[2]
Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures [J].
Austin, Matthew ;
Yang, Yu-Ching ;
Vittinghoff, Eric ;
Adami, Silvano ;
Boonen, Steven ;
Bauer, Douglas C. ;
Bianchi, Gerolamo ;
Bolognese, Michael A. ;
Christiansen, Claus ;
Eastell, Richard ;
Grauer, Andreas ;
Hawkins, Federico ;
Kendler, David L. ;
Oliveri, Beatriz ;
McClung, Michael R. ;
Reid, Ian R. ;
Siris, Ethel S. ;
Zanchetta, Jose ;
Zerbini, Cristiano A. F. ;
Libanati, Cesar ;
Cummings, Steven R. .
JOURNAL OF BONE AND MINERAL RESEARCH, 2012, 27 (03) :687-693
[3]
Denosumab and bisphosphonates: Different mechanisms of action and effects [J].
Baron, Roland ;
Ferrari, Serge ;
Russell, R. Graham G. .
BONE, 2011, 48 (04) :677-692
[4]
A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women [J].
Bekker, PJ ;
Holloway, DL ;
Rasmussen, AS ;
Murphy, R ;
Martin, SW ;
Leese, PT ;
Holmes, GB ;
Dunstan, CR ;
DePaoli, AM .
JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (07) :1059-1066
[5]
Effects of denosumab on bone mineral density and bone turnover in postmenopausal women [J].
Bone, Henry G. ;
Bolognese, Michael A. ;
Yuen, Chui Kin ;
Kendler, David L. ;
Wang, Huei ;
Liu, Yu ;
Martin, Javier San .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (06) :2149-2157
[6]
Treatment with Denosumab Reduces the Incidence of New Vertebral and Hip Fractures in Postmenopausal Women at High Risk [J].
Boonen, S. ;
Adachi, J. D. ;
Man, Z. ;
Cummings, S. R. ;
Lippuner, K. ;
Torring, O. ;
Gallagher, J. C. ;
Farrerons, J. ;
Wang, A. ;
Franchimont, N. ;
San Martin, J. ;
Grauer, A. ;
McClung, M. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (06) :1727-1736
[7]
Volumetric quantitative computed tomography of the proximal femur: relationships linking geometric and densitometric variables to bone strength. Role for compact bone [J].
Bousson, V ;
Bras, A ;
Roqueplan, F ;
Kang, Y ;
Mitton, D ;
Kolta, S ;
Bergot, C ;
Skalli, W ;
Vicaut, E ;
Kalender, W ;
Engelke, K ;
Laredo, JD .
OSTEOPOROSIS INTERNATIONAL, 2006, 17 (06) :855-864
[8]
Technology insight: noninvasive assessment of bone strength in osteoporosis [J].
Bouxsein, Mary L. .
NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2008, 4 (06) :310-318
[9]
Micro architecture, the key to bone quality [J].
Brandi, Maria Luisa .
RHEUMATOLOGY, 2009, 48 :IV3-IV8
[10]
Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/jbmr.080901, 10.1359/JBMR.0809010]